Navigation Links
Cardium Launches New AWARE Clinical Study Website
Date:6/11/2008

with diabetes.

About Generx

Generx(TM) (alferminogene tadenovec, Ad5FGF-4) is the lead product candidate in a new class of cardiovascular biologics that is being developed to leverage the body's natural healing processes in response to repeated ischemic stress (insufficient blood flow and myocardial oxygen supply due to coronary heart disease). The natural biologic response to repeated transient ischemia is angiogenesis, the growth of new collateral blood vessels, which is orchestrated by a complex and incompletely understood cascade involving many growth factors. These newly-formed vessels can effectively augment blood flow and oxygen delivery to parts of the patient's heart downstream from a blockage in a coronary artery. In many patients however, including those with recurrent angina, coronary collateral vessel formation is insufficient to meet the heart's needs during stress. Currently available anti-anginal drugs, which may provide symptomatic relief, are generally designed to alter the oxygen demand of the heart muscle or dilate vessels to temporarily relieve angina. Generx is designed to be a disease-modifying angiogenic therapeutic to promote the heart's natural response to ischemia through the growth of new blood vessels to increase blood flow within the heart muscle.

Cardium's therapeutic approach to the treatment of myocardial ischemia associated with coronary heart disease has been the focus of the most widely-conducted clinical studies for Angiogenic Gene Therapy (AGENT-1 through AGENT-4), which involved 663 patients at more than 100 U.S., European and other international medical centers. Generx represents the first and only DNA-based cardiovascular therapeutic to be advanced to Phase 3, and the Company believes it to be the only current Phase 3 product candidate for the potential treatment of patients with stable angina, a chronic medical condition affecting millions of patients in the U.S. and worldwide.

About Cardium

<
'/>"/>
SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Cardium Completes $5.3 Million Registered Direct Offering
3. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
4. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
5. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
9. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
10. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
11. Novozymes Launches Enzyme to Reduce Acrylamide in Food
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Chosen for his engaging style ... has been selected as keynote speaker for a ... will deliver his keynote: "Don't Stop Thinking About ... to the American Medical Association, Blue Cross Blue ... Forum on Wireless Healthcare, United Healthcare, IASIS Healthcare, ...
(Date:6/1/2015)... June 1, 2015  Turing Pharmaceuticals AG announced that ... Salinas , MD, MSc,  has joined the company ... Dr. Salinas, who holds a medical degree as ... record of significant accomplishments in the pharmaceutical industry, ... Dr. Salinas has played a leadership role in ...
(Date:6/1/2015)... Research and Markets ... of the "Oxidative Stress Assay Market ... (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), Technology ... Global Forecast to 2020" report to ... , The global oxidative stress ...
(Date:6/1/2015)... and YONGIN, South Korea , ... pride that Green Cross Biotherapeutics Inc. (GCBT) kicked off ... located on the Montreal Technoparc,s Saint-Laurent Campus. The CA$315 ... investment projects in Canada in ... the first intravenous immunoglobulin (IVIG) and albumin manufacturing plant ...
Breaking Biology Technology:Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3
... Committee Recommendation in European UnionSAN MATEO, Calif., March 19 ... biopharmaceutical company focused on developing and commercializing novel pain ... call on Friday, March 20, 2009 at 9:00 a.m. ... year-end 2008 results and the European Medicines Agency,s (EMEA) ...
... Solutions, a global life sciences technology solutions company ... that one of the world,s largest pharmaceutical companies ... System. This system provides a powerful, flexible ... lifecycle... from proposal to publication... helping to ensure ...
... will allow the recycling and conversion of 60% ... 19 /PRNewswire/ - Enerkem Inc., a leading advanced ... its plans to build and operate a second-generation ... In addition, the company announced the signature of ...
Cached Biology Technology:NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update 2NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update 3NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update 4Top Ten Pharma Company Deploys MedNet Solutions' Investigator Initiated Trial Management System 2Enerkem announces plans to enter the United States with next-generation biofuels project in Mississippi 2Enerkem announces plans to enter the United States with next-generation biofuels project in Mississippi 3
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... Early-stage human clinical trials showed that a new topical drug ... diabetic eye disease, and may offer researchers a new approach ... the Wilmer Eye Institute of Johns Hopkins University School of ... diabetic macular edema with mecamylamine, a topical drug developed by ...
... --- With loggerhead sea turtle nests in dramatic decline, researchers ... and what they eat, so they can better protect the ... biologists from the Archie Carr Center for Sea Turtle Research ... surprising findings. Doctoral student Hannah Vander Zanden writes in ...
... for Microbiology (ASM) will hold its 110th General ... The meeting will feature approximately 3,000 individual ... has an expected attendance of 10,000. Microbiologists ... work is critical to human and animal health, ...
Cached Biology News:JDRF funded researchers test topical drug to treat diabetic macular edema 2JDRF funded researchers test topical drug to treat diabetic macular edema 3Increasingly threatened loggerheads follow their own paths in travel, eating 2Increasingly threatened loggerheads follow their own paths in travel, eating 3American Society for Microbiology to host 110th general meeting in San Diego 2
... multi-cell is for 2-D separations. The cell has ... PROTEAN II xi multi-cell can be customized for ... plates, and cooling system. The PROTEAN II xi ... II XL multi-cell for a wider format that ...
F40 piston seals are supplied as 2 seals with a seal tool to service one F40 pump of a BioLogic DuoFlow workstation....
... Cell permeable fluorescent minor groove-binding probe ... of double-stranded DNA (preferentially to AT rich ... approximately 20 times greater than DAPI alone. ... ethidium bromide for staining DNA in agarose ...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
Biology Products: